Ironwood Pharmaceuticals
IRWD
254 hedge funds and large institutions have $1.74B invested in Ironwood Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 106 increasing their positions, 79 reducing their positions, and 21 closing their positions.
1,273% more call options, than puts
Call options by funds: $412K | Put options by funds: $30K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
34% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 79
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
2% more funds holding
Funds holding: 249 → 254 (+5)
0.24% less ownership
Funds ownership: 107.02% → 106.78% (-0.24%)
14% less capital invested
Capital invested by funds: $2.03B → $1.74B (-$291M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$20M |
| 2 |
Morgan Stanley
New York
|
+$12.8M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.4M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$7.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$80.2M |
| 2 |
Millennium Management
New York
|
-$29.2M |
| 3 |
Man Group
London,
United Kingdom
|
-$15.5M |
| 4 |
JP Morgan Chase
New York
|
-$15.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.82M |
IRWD Hedge Fund Activity: Q1 2023 in Review
254 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2023, worth a combined $1.74B — down 14% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new IRWD positions and 21 closed out — a net gain of 7 holders — while 106 added to existing stakes and 79 trimmed.
The largest buyer was Jane Street, adding an estimated $20M. The largest seller was Wellington Management Group, cutting an estimated $80.2M.
- 254 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2023, up from 249 in Q4 2022.
- Funds reported $1.74B of Ironwood Pharmaceuticals stock for Q1 2023, down 14% quarter-over-quarter.
- 28 funds opened new Ironwood Pharmaceuticals positions in Q1 2023 and 21 closed out, a net change of +7 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2023 was Jane Street, an estimated $20M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2023 was Wellington Management Group, an estimated $80.2M sold.
Based on aggregated 13F filings for Q1 2023.